Pharmaceutical Investing Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
Pharmaceutical Investing Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
Pharmaceutical Investing PADCEV Plus KEYTRUDA, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
Pharmaceutical Investing TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
Pharmaceutical Investing Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
Pharmaceutical Investing Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
Pharmaceutical Investing Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
Pharmaceutical Investing Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Pharmaceutical Investing Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
Pharmaceutical Investing Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
Pharmaceutical Investing Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pharmaceutical Investing PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
